Moldova is fully dependent on imported medicines
The pharmaceutical market continued to grow its imports of drugs and medical devices in 2025, registering a growth of 5.39% in value (euros) and 3.69% in volume (boxes).
The data is cited by the Agency for Medicines and Medical Devices in its annual report, noting that the difference between the value and volume of imports is due to “a focus on more innovative and therefore more expensive treatments”.
The main producers of imported medicines include, as before, 5 large research and development companies, 3 European generic companies and 2 companies whose production is mainly concentrated in Turkey.
All licensed distributors in Moldova have GDP (Good Distribution Practice) certificates or are in the process of certification. The three largest importers account for 80% of the total volume of imported products.
This emphasizes the high degree of market concentration, which poses a threat to the security of the pharmaceutical market: low competition allows distributors to “hold” prices and creates a risk of shortages in case of supply problems.
Traditionally, the leading positions are held by companies with their own wide network of pharmacies: Dita EstFarm (Farmacia Familiei chain of pharmacies), Tetis International Co, Medeferent Grup (Hippocrates chain of pharmacies) or Felicia.
